Course Information

Release date: October 13, 2026

Expiration date: October 13, 2027

Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by an educational grant from Genentech, a member of the Roche Group.

PROGRAM OVERVIEW

Chronic spontaneous urticaria (CSU) is a chronic, relapsing, mast cell–driven inflammatory disease that can significantly impair sleep, productivity, mental health, and overall quality of life. Despite established treatment guidelines, many patients continue to experience delayed diagnosis, inconsistent disease assessment, and prolonged uncontrolled symptoms. FDA-approved indications for dupilumab and remibrutinib have expanded treatment options beyond anti-immunoglobulin E (IgE) therapy, creating new opportunities and challenges for clinicians navigating an increasingly complex therapeutic landscape.

This In the Clinic activity will provide practical, evidence-based guidance on diagnosis, disease activity assessment using validated tools, treatment escalation, and mechanism-based therapy selection. Through expert-led discussions and real-world clinical cases, participants will gain actionable strategies for incorporating existing and emerging therapies into personalized, guideline-aligned care to improve patient outcomes and reduce the burden of uncontrolled CSU.

Learning Objectives

TARGET AUDIENCE

This educational activity has been designed for dermatologists, allergy and immunology specialists, and other healthcare providers who manage patients with CSU.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Explain the key immune and cellular pathways that drive CSU and how they relate to targeted treatment mechanisms
Apply guideline-recommended diagnostic and disease-activity assessment tools, including UAS7 and AAS7, to evaluate patients with suspected or confirmed CSU
Identify clinical indicators of inadequate response and outline appropriate escalation strategies for antihistamine-refractory CSU
Compare the mechanisms, clinical roles, and evidence for currently approved and emerging therapies for CSU

Faculty Information and Disclosures

FACULTY

Shawn G. Kwatra, MD

Professor and Chairman of Dermatology 

University of Maryland School of Medicine 

Baltimore, Maryland 

Marc A. Riedl, MD, MS 

Professor of Medicine

HAE Community Endowed Chair

Vice Chair of Clinical Research

Department of Medicine

Clinical Director, US HAEA Angioedema Center

Clinical Service Chief

Division of Allergy & Immunology

University of California

San Diego, California 

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Shawn G. Kwatra, MD

Consultant: AbbVie, Apogee, Bambusa Therapeutics, Eli Lilly, Galderma, Incyte, Johnson & Johnson, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi

Speaker: Galderma, Incyte

Sponsored Research: Galderma, Incyte, Pfizer, Regeneron

Marc A. Riedl, MD, MS

Consulting: ADARx, Astria, BioCryst, Celldex, CSL Behring, Grifols, Intellia, Ionis, KalVista, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda

Research Support: ADARx, Astria, BioCryst, CSL Behring, Intellia, Ionis, KalVista, Pharvaris, Takeda

Speaker (Unbranded): BioCryst, CSL Behring, Grifols, Pharming, Pharvaris, Takeda

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 13, 2026 to October 13, 2027, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 25% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Improving Care Pathways for Patients With Chronic Spontaneous Urticaria: From Disease Recognition to Biologic and Targeted Therapy Utilization